Immunobiologics are used to treat patients with moderate to severe psoriasis and allow for continuous maintenance therapy for longer periods of time without the adverse effects seen with older systemic medications, such as methotrexate or cyclosporine. However, will patients stop responding to the drug if they discontinue and restart therapy? This review will examine four biologic agents currently used in the treatment of psoriasis – etanercept, adalimumab, infliximab, and ustekinumab — to determine whether patients can re-achieve comparable clinical response with intermittent therapy versus continuous therapy. While some data suggest that continuous immunologic therapy may lead to decreased efficacy over time, etanercept, adalimumab, and ustekinumab provide patients with durable response should a patient need to discontinue and reinitiate treatment. These findings may assist clinicians in selecting an appropriate agent should interruption of therapy be necessary.
KooJ., LebwohlM.Duration of remission of psoriasis therapies. J Am Acad Dermatol.1999 Jul; 41(1): 51–9.
2.
Callis-DuffinK., YeungH., TakeshitaJ.Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. First published online March 12, 2014. 170: 672–680. doi: 10.1111/bjd.12745.
3.
KamangarF., IsipL., BhutaniT., DennisM., HellerM.How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. J Dermatol Treatment.2013; 24: 13–24.
4.
LebwohlM.A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. July 2005; S60–S68.
5.
LecluseL.L., DriessenR.J., SpulsP.I.Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol.2010 Feb; 146(2): 127–32.
6.
LeonardiC.L., PowersJ.L., MathesonR.T.Etanercept as Monotherapy in Patients with Psoriasis. N Engl J Med.2003 November 20; 349: 2014–2022.
7.
GordonK.B., GottliebA.B., LeonardiC.L.Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat.2006; 17(1): 9–17.
8.
AbucharA., VitelloM., RicottC.Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis. J Drugs Dermatol.2012 August; 11(8): 950–954.
9.
SiegfriedE., EichenfieldL., PallerA.Intermittent therapy in pediatric patients with psoriasis. J Am Acad Dermatol.2010 Nov; 63(5): 769–774.
10.
LarianA., EmerJ., GordonK.Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients Who Relapsed After Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial. Psoriasis Forum. Summer 2011; 17(2): 88–96.
11.
MenterA., TyringS.K., GordonK.Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol.2008 Jan; 58(1): 106–15.
12.
GordonK., BlumR., PappK.Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial. Psoriasis Forum.2007 Summer; 13(1): 4–11.
13.
PappK., CrowleJ., OrtonneJ.P.Adalimumab for moderate to severe chronic psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol.2011; 164: 434–441.
14.
PappK., MenterA., PoulinY., GuY., SassoE.H.Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol.2013 May; 27(5): 634–42.
15.
GottliebA.B., ChaudhariU., MulcahyL.D.Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol.2003 Jun; 48(6): 829–35.
16.
ChaudhariU., RomanoP., MulcahyL.D.Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet.2001 Jun 9; 357(9271): 1842–7.
17.
MenterA., FeldmanS., WeinsteinG.A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol.2007 January; 56(1): 31.e1–31.e15.
18.
KimballA., GordonK., FakharzadehS.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol.2012 Apr; 166(4): 861–72.
19.
LeonardiC.L., KimballA., PappK.A.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet.2008 May 17; 371(9625): 1665–74.
20.
LebwohlM.A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol.2005 Jul; 53(1 Suppl 1): S59–69.
21.
GordonK.B., GandhiM.Strategies for Treatment with Anti-Tumor Necrosis Factor Agents in Psoriasis: Maintaining Efficacy and Safety for the Long Haul. Arch Dermatol.2010; 146(2): 186–188.
22.
LebwohlM., PappK., HanC.Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol.2010 Jan; 162(1): 137–46.
23.
RevickiD.A., WillianM.K., MenterA.Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology.2008; 216260–270.
24.
AhnC., GustafsonC., SandovalL., DavisS., FeldmanS.Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol.2013; 14: 315–326.
25.
ArmstrongA.W., RobertsonA.D., WuJ., SchuppC., LebwohlM.G.Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003–2011. JAMA Dermatol.2013; 149(10): 1180–1185.
